These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31061697)

  • 1. Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study.
    Fauske L; Hompland I; Lorem G; Bondevik H; Bruland ØS
    Clin Sarcoma Res; 2019; 9():6. PubMed ID: 31061697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: a qualitative study with patients and medical oncologists.
    van de Wal D; Fauske L; Bruland ØS; Jones RL; Kasper B; Wilson R; van der Graaf WTA; Husson O
    Support Care Cancer; 2023 May; 31(6):352. PubMed ID: 37233829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striving towards Normality in Daily Life: A Qualitative Study of Patients Living with Metastatic Gastrointestinal Stromal Tumour in Long-Term Clinical Remission.
    Fauske L; Hompland I; Lorem G; Hall KS; Bondevik H
    Sarcoma; 2020; 2020():1814394. PubMed ID: 33082706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A patient's perspective on the side effects of tyrosine kinase inhibitors in the treatment of advanced and metastatic gastrointestinal stromal tumors.
    van de Wal D; Venkatesan S; Benson C; van der Graaf WTA; Johnson CD; Husson O; Sodergren SC
    Future Oncol; 2023 Feb; 19(4):299-314. PubMed ID: 37038981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experiences and perspectives on the GIST patient journey.
    Macdonald N; Shapiro A; Bender C; Paolantonio M; Coombs J
    Patient Prefer Adherence; 2012; 6():253-62. PubMed ID: 22536061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours.
    Fauske L; Wærstad PH; Hompland I; Bruland ØS
    Anticancer Res; 2022 Feb; 42(2):955-963. PubMed ID: 35093895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study.
    Tan AD; Willemsma K; MacNeill A; DeVries K; Srikanthan A; McGahan C; Hamilton T; Li H; Blanke CD; Simmons CE
    Curr Oncol; 2020 Jun; 27(3):e276-e282. PubMed ID: 32669934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
    Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.
    Nannini M; Nigro MC; Vincenzi B; Fumagalli E; Grignani G; D'Ambrosio L; Badalamenti G; Incorvaia L; Bracci R; Gasperoni S; Saponara M; Gatto L; Indio V; Astolfi A; Di Scioscio V; Casali PG; Tonini G; Aglietta M; Russo A; Biasco G; Pantaleo MA
    Ther Adv Med Oncol; 2017 Dec; 9(12):731-739. PubMed ID: 29449894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Keung EZ; Fairweather M; Raut CP
    Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
    Pilotte AP
    Curr Med Res Opin; 2015; 31(7):1363-76. PubMed ID: 25912466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal stromal tumors (GIST) related emergencies.
    Sorour MA; Kassem MI; Ghazal Ael-H; El-Riwini MT; Abu Nasr A
    Int J Surg; 2014; 12(4):269-80. PubMed ID: 24530605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional Treatments for Metastatic Gastrointestinal Stromal Tumor in British Columbia: A Retrospective Cohort Study from January 2008 to December 2017.
    Patterson T; Li H; Chai J; Debruyns A; Simmons C; Hart J; Pollock P; Holloway CL; Truong PT; Feng X
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the body image of bone sarcoma survivors following surgical treatment--A qualitative study.
    Fauske L; Lorem G; Grov EK; Bondevik H
    J Surg Oncol; 2016 Feb; 113(2):229-34. PubMed ID: 26714610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.